Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 196,391,280
  • Shares Outstanding, K 2,365,590
  • Annual Sales, $ 49,436 M
  • Annual Income, $ 6,712 M
  • 36-Month Beta 0.72
  • Price/Sales 4.03
  • Price/Cash Flow 17.33
  • Price/Book 2.70

Price Performance

See More
Period Period Low Period High Performance
1-Month
80.60 +4.19%
on 10/27/17
86.61 -3.04%
on 10/19/17
-2.36 (-2.73%)
since 10/17/17
3-Month
80.60 +4.19%
on 10/27/17
86.87 -3.33%
on 10/16/17
+0.80 (+0.96%)
since 08/17/17
52-Week
66.93 +25.47%
on 12/08/16
86.90 -3.36%
on 06/22/17
+11.44 (+15.77%)
since 11/17/16

Most Recent Stories

More News
Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion

Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.

NVS : 83.98 (+1.16%)
RHHBY : 29.1000 (+0.71%)
PFE : 35.37 (-0.53%)
BMY : 61.32 (-0.89%)
Celgene CAR-T Therapy Gets Breakthrough Therapy Designation

FDA grants Breakthrough Therapy Designation to Celgene's (CELG) chimeric antigen receptor T-cell (CAR-T) therapy candidate, bb2121.

CELG : 104.10 (+0.73%)
BLUE : 163.20 (+1.90%)
NVS : 83.98 (+1.16%)
GILD : 72.44 (+0.04%)
Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?

Alnylam (ALNY) expects to achieve the profile of three marketed products by the end of 2020 and remains focused on development of its pipeline candidates.

ALNY : 127.51 (+0.89%)
NVS : 83.98 (+1.16%)
RHHBY : 29.1000 (+0.71%)
SNY : 44.54 (-0.25%)
Biden Cancer Initiative, Michael J. Fox Foundation for Parkinson's Research, Novartis and Others Support Bridging Clinical Research & Clinical Health Care Collaborative

The Bridging Clinical Research & Clinical Health Care Collaborative, to be held April 4-5 near Washington, D.C., will bring together leaders from pharma, biotech, clinical research...

NVS : 83.98 (+1.16%)
Incyte (INCY) Initiates Essential Thrombocythemia Trial

Incyte (INCY) announced that the first patient has been treated in the essential thrombocythemia trial on ruxolitinib. A potential label expansion of the drug will boost sales.

CORT : 18.39 (-3.46%)
SCMP : 10.55 (+1.93%)
INCY : 105.47 (-0.95%)
NVS : 83.98 (+1.16%)
Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test

Roche's (RHHBY) diagnostic portfolio gets a further boost with FDA's clearance for Ventana tests.

CORT : 18.39 (-3.46%)
SCMP : 10.55 (+1.93%)
NVS : 83.98 (+1.16%)
RHHBY : 29.1000 (+0.71%)
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania

Novartis International AG / Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible...

NVS : 83.98 (+1.16%)
Conquest Firespray Is Supplying Flamebar(R) Fire-Rated, Code-Compliant HVAC Ducts to A-List Developments Nationwide

Conquest Firespray, a manufacturer of Flamebar(R) coated fire-rated architectural and engineered HVAC duct systems, today announced that it has played a key role in preventing potential...

CMCSA : 36.16 (-2.45%)
NVS : 83.98 (+1.16%)
MAR : 125.48 (+0.88%)
Novartis (NVS) Arm's Biosimilars Study Results Encourage

Novartis (NVS) generic arm, Sandoz, reported positive data from two phase III studies evaluating biosimilars of Humira and MabThera respectively.

NVS : 83.98 (+1.16%)
ABBV : 93.61 (-0.91%)
RHHBY : 29.1000 (+0.71%)
AMGN : 170.00 (-0.45%)
New data reinforces clinical basis for switching to Sandoz biosimilar medicines

Novartis International AG / New data reinforces clinical basis for switching to Sandoz biosimilar medicines . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for...

NVS : 83.98 (+1.16%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 84.90
1st Resistance Point 84.44
Last Price 83.98
1st Support Level 83.38
2nd Support Level 82.78

See More

52-Week High 86.90
Last Price 83.98
Fibonacci 61.8% 79.27
Fibonacci 50% 76.92
Fibonacci 38.2% 74.56
52-Week Low 66.93

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart